Czech Republic Jakub Dvořáček, CEO of the Czech Association of Innovative Pharmaceutical Industry (AIFP), describes the thorough review of the reimbursement scheme the association has worked on alongside other key stakeholders in Czech healthcare and evaluates the major change this will bring in terms of access to innovative medicines for patients. Furthermore,…
Czech Republic A current lack of transparency in Czech healthcare spending is severely detrimental to all industry stakeholders. However, new synergies between the private and public sectors are helping to clear these murky waters. The Czech Republic, with a population of about 10.5 million, is the third most populous country within Central…
Asociace inovativního farmaceutického průmyslu (AIFP) Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can you begin by expounding the results of this study? The footprint of the innovative pharma industry in this market is not particularly large relative to other industries,…
See our Cookie Privacy Policy Here